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Abstract Chronic hepatitis B infection (HBV) is the
major cause of primary liver cancer worldwide and Asians
are disproportionately affected. The prevalence of HBV
among most Asian American groups has been well docu-
mented, except in Hmong immigrants in the United States.
The aim of this study was to determine the prevalence of
HBV among Hmong immigrants in the San Joaquin Valley
of California. A convenient sample of 534 Hmong age
C18 years was recruited at various locations throughout
Fresno County. Blood samples from study participants
were collected and tested for hepatitis B surface antigen
(HBsAg) by enzyme-immunoassay. Two hundred and
eighty-nine females and 245 males of Hmong descent
(mean age, 43.93) were screened. Eighty-nine (41 males
and 48 females) were positive for HBsAg, which accounts
for a prevalence of 16.7% (95% C.I. 13.5–19.9). The
majorities of HBsAg positive patients were C40 years
(64.2%), married (66.7%), born in Laos (87.3%), and had
lived in the United States C20 years (62.5%). Only 37.5%
of the participants reported having a primary care
physician. Our study revealed that approximately one out
of every six Hmong immigrants screened was infected with
HBV. Based on our ﬁndings, more than one-third of these
infected patients have no primary care physician to provide
further treatment, surveillance for liver cancer, or vacci-
nation of their families. This supports the Institute of
Medicine’s recent recommendations to the Center for
Disease Control to engage in a national Hepatitis B sur-
veillance system.
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Introduction
HBV is endemic in the Asia–Paciﬁc region. Many studies
have suggested that this is due to vertical transmission from
mother to newborn coupled with low vaccination rates [1,
2]. Approximately 90% of infants and 25–50% of children
aged 1–5 years will remain chronically infected with HBV
after exposure [3]. Twenty-ﬁve percent of those who
become chronically infected during childhood and 15% of
those who become chronically infected after childhood die
prematurely from cirrhosis or liver cancer [4, 5]. In the
United States, there are an estimated 1.25 million people
with chronic HBV infection [6, 7]. The prevalence of
chronic HBV infection in Asian Americans is between 10
and 15% compared to only 0.3% for the general United
States population [8]. Chronic HBV infection is a major
cause of hepatocellular carcinoma (HCC). A recent Tai-
wanese study reported 94.9% infection rate with HBV at
the time of HCC diagnosis [9]. HCC is the leading cause of
death among Asian Americans between the ages of 25–65
[10–12]. In the United States, chronic HBV infection
results in estimated 2,000–4,000 deaths per year [3].
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reside in the United States; of these, 5–10% of ﬁrst-gen-
eration immigrants may be chronically infected with HBV.
Thus, the true prevalence of chronic HBV infection is
probably in excess of 2 million. On the basis of immigra-
tion patterns in the last decade, it is estimated that every
year 40,000–45,000 people from HBV-endemic countries
legally immigrate to the United States. In addition,
approximately 45,000 new HBV infections occur each
year. The prevalence of HBsAg among Asian refugees
entering the United States between 2006 and 2008 has been
reported as 4.8% [13]. In 2001, the lead author of our study
participated in a prospective survey of Vietnamese immi-
grants in Orange County, California and found that 12.9%
were HBsAg positive [14].
Several studies have demonstrated the prevalence of
HBV among other Asian groups in the United States,
however, there are no prospective data available for the
Hmong population. A retrospective study conducted in St.
Paul, Minnesota found that Hmong Americans have an
18% prevalence of HBV, with the rate of infection being
highest among patients who were between 15 and 19 years
of age [15]. Another retrospective study from Michigan
reported that Hmong Americans had the highest prevalence
rate of HBV infection among those screened [16].
In the mid 1970s after the Vietnam War, large numbers
of Hmong began arriving in the United States as refugees
from Laos. According to the United States Census bureau
in 2000, there were approximately 186,310 Hmong in the
United States. The San Joaquin Valley in California is one
of the fastest growing Hmong communities with a popu-
lation estimated at 65,095 [17]. There are limited data
regarding the health status of the Hmong in central valley
especially morbidity and mortality associated with cancer
[18, 19]. To date, there is no prospective HBV screening
study in the Hmong population. Therefore, the prevalence
of HBV among Hmong in San Joaquin Valley remains
unknown. Such screening is essential to educate this pop-
ulation about the risks associated with HBV and optimize
strategies for early detection and prevention of HCC [20–
22]. The objective of this HBV screening study was to
determine the prevalence of HBV among Hmong popula-
tion residing in Fresno County.
Methods
Sampling and Recruitment
Serological screening was provided to 534 Hmong age
C18 years between December 2006 and December 2008.
Recruiting efforts took place at many popular Hmong
locations in the Fresno area. Local Hmong were made
aware of the screening through several means including
newspaper, frequent radio announcements, and ﬂyers in
Hmong. Educational slide presentations were delivered at
Hmong church gatherings prior to all screening sessions.
Two consecutive years at the International Hmong New
Year Celebration in Fresno, stations for screening were
established and educational material was provided. Blood
samples were collected, coded, centrifuged on-site, and
serum was tested for HBsAg by enzyme-immunoassays at
a local laboratory.
After signing an informed consent, the study participants
were given a choice of either a Hmong or English demo-
graphic and medical history questionnaire to complete.
Hmong research volunteers assisted the participants in
completing the questionnaire. All participants were notiﬁed
of their blood test result through a conﬁdential letter. Those
who were found positive for HBsAg were invited for
counseling. They were educated on the modes of trans-
mission, complications of infection, prevention strategies
and treatment options of HBV. The University of Califor-
nia, San Francisco—Fresno Institutional Review Board
approved all study procedures.
Data Analysis
The presence of HBsAg in serum was determined by
enzyme-immunoassays. Descriptive statistics were calcu-
lated and reported for demographic variables such as: age,
sex, birthplace, years lived in US, marital status, vaccina-
tion, and establishment of care with a primary care pro-
vider. Ninety-ﬁve percent conﬁdence intervals (CIs) were
calculated for each variable.
Results
A total of 534 Hmong were screened for HBV infection. Of
these 45.9% (n = 245) were males and 54.1% (n = 289)
were females. The mean age was 43.94 (SD = 15.62), the
range being 18–90 years. The majority of the participants
(88.1%, n = 457) were born outside of the United States,
mainly in Laos (80.9%). Only 37.5% (n = 200) of the
participants indicated that they had a primary care physi-
cian. The duration of residence in the United States was
categorized into 10-year intervals, and the majority
(63.6%) had lived in the United States for about 20–
29 years. These characteristics are summarized in Table 1.
Of 534 participants tested for HBsAg, 89 (41 males and
48 females) were tested positive for HBsAg with a prev-
alence of 16.7% (95% CI 13.5–19.9). Among these sub-
jects, the mean age was 45.22 years (SD = 17.35) with a
range of 18–89 years. Nearly 92% (n = 79) were born
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Laos. The majority were married (67.7%, n = 56) and
53.1% (n = 17) had been living in the United States for
about 20–29 years. Among these infected subjects, only
37.1% (n = 33) reported having a primary care physician
(Table 1).
Discussion
Our study found that 16.7% of Hmong in the San Joaquin
Valley might be chronically infected with HBV. We did
not evaluate the mode of transmission of HBV among the
study participants. However, the literature suggests that the
majority of Asians contract the virus during birth or in their
early childhood [1, 2]. Our study showed that nearly 92%
(n = 79) of HBsAg positive patients were born outside the
United States. It is most likely that this Hmong population
was already infected at the time of immigration to the
United States. Our study found that nearly 75% (n = 63) of
those who tested positive for HBV infection were married
or previously married. Engaging in high risk behavior, such
as having multiple sex partners, tattooing, and injecting
drugs are not common practices in this community. A
similar observation was made among Hmong in Thailand
in an earlier study [23]. The majority of the participants
were unaware of any known liver disease. These ﬁndings
are compatible with previously published data in Asian
populations [24–28].
Rein et al. [13] published a recent study reporting the
prevalence of HBsAg among refugees entering the United
States during 2006–2008. They report a prevalence of 6.5%
in Eastern Asians and 10.5% in Southeast Asians. The
prevalence in those from Vietnam and Laos were 3.2 and
2.3%, respectively. However, this study was limited due to
lack of information about the age and sex of the refugees.
In comparison to CDC data from 1991 [29], the prevalence
in Hmong refugees decreased from 15.5 to 2.3% in 2008.
This 1991 prevalence for Laos was reported for the Hmong
and for other Laotians without a single population-wide
estimate. The decline in prevalence may be attributed to
many factors, such as increased vaccination. The preva-
lence of 15.5% reported in 1991 is more consistent with the
prevalence reported in our study because the majority
(53.1%) of the Hmong we screened had lived in the United
States for 20–29 years.
There are several limitations to our study. First, the free
HBV screening sites were all located in Fresno County.
Therefore, our ﬁndings may not be generalized to the
Hmong population in other parts of the United States, or
even to the entire Hmong population in the Central Valley
due to our sampling frame. Second, the reluctance of this
population to participate in screening may have affected
the true prevalence. Many Hmong were afraid of getting
their blood drawn and were apprehensive of the results.
They were also worried about their family members
knowing their health status. In the Hmong and other Asian
American communities, hepatitis B may be stigmatized
with having sexual partners, which can lead to ostracism.
These observations are consistent with ﬁndings from other
Asian American screening studies [24–28]. Therefore, the
Table 1 Prevalence of hepatitis B virus (HBV) infection among
screened participants by selected demographic characteristics
Characteristics n (%) HBsAg positive
n (%) (95% CI)
Gender
Male 245 (45.9) 41 (16.7) (12.0–21.4)
Female 289 (54.1) 48 (16.6) (12.3–20.9)
Marital status
Single 134 (25.1) 21 (15.7) (9.5–21.9)
Married 345 (64.6) 56 (16.2) (12.3–20.1)
Previously married 34 (6.4) 7 (20.6) (7.0–34.2)
No response 21 (3.9) 5 (23.8) (5.6–42.0)
Age group (years)
\30 105 (19.7) 18 (17.1) (9.9–24.3)
30–39 75 (14) 11 (14.7) (6.7–22.7)
40–49 125 (23.4) 22 (17.6) (10.9–24.3)
50–59 104 (19.5) 14 (13.5) (6.9–20.1)
60–69 44 (8.2) 11 (25) (12.2–37.8)
C70 27 (5.1) 5 (18.5) (3.9–33.1)
No response 54 (10.1) 8 (14.8) (5.3–24.3)
Country of birth
Laos 420 (78.7) 69 (16.4) (12.9–19.9)
United States 62 (11.6) 7 (11.3) (3.4–19.2)
Thailand 28 (5.2) 7 (25) (9.0–41.0)
Other 9 (1.7) 3 (33.3) (2.5–64.1)
No response 15 (2.8) 3 (20) (0.0–40.2)
Years in United States
\10 10 (1.9) 2 (20) (0.0–44.8)
10–19 39 (7.3) 10 (25.6) (11.9–39.3)
20–29 119 (22.3) 17 (14.3) (8.0–20.6)
[30 19 (3.6) 3 (15.8) (0–32.2)
No response 347 (65) 57 (16.4) (12.5–20.3)
Have primary care provider (self-report)
Yes 200 (37.5) 33 (16.5) (11.4–21.6)
No 15 (2.8) 4 (26.7) (4.3–49.0)
No response 319 (59.7) 52 (16.3) (12.2–20.4)
Vaccinated against hepatitis B (self-report)
Yes 61 (11.4) 10 (16.4) (7.1–25.7)
No/not sure 333 (62.4) 53 (15.9) (12.0–19.8)
No response 140 (26.2) 26 (18.6) (12.2–25.0)
Overall 534 89 (16.7) (13.5–19.9)
Hepatitis B surface antigen (HBsAg) tested positive
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of the true prevalence. Nearly 62.4% of the 534 screened
Hmong indicated that they were not vaccinated or were
unsure of their vaccination status. The majority of these
patients had no primary care physician to provide further
treatment, screening for liver cancer, or offer vaccination
and preventive measures to curtail the transmission of
HBV to their families.
The viral hepatitis surveillance system in the United
States has been highly fragmented and poorly developed.
There is a paucity of knowledge and awareness about
chronic viral hepatitis on the part of health care and social
service providers, at risk populations, members of the
public, and policy makers. There is insufﬁcient under-
standing about the extent and seriousness of this public
health problem and inadequate public resources have been
allocated to prevention, control, and surveillance programs.
Due to inaccurate estimates of the burden of disease in the
United States, policy-makers and the state governments
could not allocate sufﬁcient resources to viral hepatitis
prevention and control programs. Between 2007 and 2008,
the California Department of Health provided vaccination
against hepatitis B to nearly 30,000 individuals. However,
Asians Americans comprised only 7% of the vaccinated
population. STD clinics made up 63% of the setting in
which vaccination occurred, with community medical
centers only accounting for 7% [30].
The Centers for Disease Control and Prevention has
been recently recommended by the Institute of Medicine to
conduct a comprehensive evaluation of the national viral
hepatitis public health surveillance system. As per these
recommendations [31] there is a need to develop speciﬁc
cooperative viral hepatitis agreements with all state and
county health departments to support core surveillance for
viral hepatitis. This cooperative effort would support and
conduct targeted active surveillance, including serologic
testing, to monitor incidence and prevalence of viral hep-
atitis in populations not fully captured by core surveillance.
The collaboration would allow key stakeholders to develop
innovative and effective educational outreach programs to
at risk individuals while increasing awareness in the gen-
eral population.
Hepatitis B infection and its complications such as cir-
rhosis and HCC are largely preventable. We hope that
adherence to the Institute of Medicine’s recommendations
will provide an opportunity to decrease the impact of this
disease in Asian Americans as well as the entire global
community.
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